Omnicell to Release First Quarter 2022 Financial Results on April 28, 2022

Rhea-AI Summary

Omnicell, Inc. (NASDAQ:OMCL) will release its Q1 2022 financial results on April 28, 2022, after market close. The company will hold a conference call at 1:30 p.m. PT to discuss the results. Interested parties can join by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally, using Conference ID 5370673. The press release also highlights Omnicell's commitment to transforming pharmacy care through automation and technology to enhance operational efficiency and patient safety.

Positive

• Omnicell's solutions aim to improve medication management and patient safety.
• The company continues its strategy of innovation in pharmacy care delivery.

Negative

• Potential risks related to competition in the medication management market.
• Dependence on a limited number of suppliers for critical components.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the first quarter 2022, after market on Thursday, April 28, 2022. The Company will host a conference call and webcast to discuss its financial results at 1:30 p.m. PT that same day.

All interested parties are invited to listen to the live call and presentation by dialing (888) 550-5424 in the U.S. or (646) 960-0819 in international locations. The Conference ID is 5370673. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/events-and-presentations/.

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Healthcare facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. Institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks and Omnicell One is a trademark of Omnicell, Inc. or one of its subsidiaries.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to planned new products and services and the related expected benefits (and any implied financial impact), and statements about Omnicell’s strategy, plans, objectives, goals, and vision. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) risks related to the ongoing COVID-19 pandemic (including new variants of the virus), (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iv) unfavorable general economic and market conditions or reduction in demand for our solutions, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (vi) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, (vii) Omnicell’s ability to protect its intellectual property, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (x) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xi) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

OMCL-E

View source version on businesswire.com: https://www.businesswire.com/news/home/20220405006102/en/

Kathleen Nemeth

Senior Vice President, Investor Relations

ir@omnicell.com

Source: Omnicell, Inc.

FAQ

What date will Omnicell release its Q1 2022 financial results?

Omnicell will release its Q1 2022 financial results on April 28, 2022.

What time is the Omnicell conference call for Q1 2022 results?

The conference call for Omnicell's Q1 2022 results is scheduled for 1:30 p.m. PT.

How can I listen to the Omnicell Q1 2022 conference call?

You can listen to the Omnicell Q1 2022 conference call by dialing (888) 550-5424 in the U.S. or (646) 960-0819 internationally.

What is Omnicell's stock symbol?

Omnicell's stock symbol is OMCL.